Semaglutide Type 1 Diabetes: Evidence & Biomarker Context

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide, a GLP-1 receptor agonist, is generating research interest in type 1 diabetes management, though current clinical evidence remains limited compared to its established use in type 2 diabetes and obesity. Most regulatory approvals and extensive trials focus on type 2 applications, creating a knowledge gap for type 1 patients exploring GLP-1 options.

Type 1 diabetes management requires distinct consideration because it involves autoimmune insulin deficiency rather than insulin resistance. Understanding individual metabolic predispositions, biomarker patterns, and clinical readiness through provider-guided assessment is critical before considering any GLP-1 therapy in this population.

Type 1 Diabetes and GLP-1 Mechanisms: Why the Evidence Gap Exists

GLP-1 receptor agonists work by stimulating insulin secretion, slowing gastric emptying, and reducing appetite. In type 1 diabetes, endogenous insulin production is severely compromised due to autoimmune beta-cell destruction, fundamentally altering how these medications function compared to type 2 scenarios.

Published type 1 diabetes studies remain small and primarily exploratory. A 2022 systematic review identified limited randomized controlled trials, with most evidence derived from case reports or observational data. This contrasts sharply with extensive type 2 diabetes and obesity trial portfolios, underscoring the need for cautious provider-guided decision-making.

Clinical Evidence Framework: What Research Currently Shows

Existing type 1 research suggests potential benefits in glycemic control and weight management, though mechanisms differ from type 2. Most investigations explore whether GLP-1 agonists reduce insulin requirements, improve A1C outcomes, or lower hypoglycemia risk in insulin-dependent patients already using basal-bolus or pump therapy.

Evidence Category	Current Findings	Provider Consideration
A1C Reduction	Small studies show modest reductions (0.3–0.8%); heterogeneous outcomes	Outcomes vary by individual; provider assessment essential
Insulin Requirement	Some trials report 10–20% reduction in daily insulin dose	Dose adjustments require close monitoring and titration support
Weight Management	GLP-1 effects on appetite/satiety observed in type 1 cohorts	May benefit overweight/obese type 1 patients; individualized risk-benefit needed
Hypoglycemia Risk	Conflicting data; potential reduction reported but not consistently proven	Requires careful baseline assessment and ongoing provider supervision
Cardiovascular Outcomes	No dedicated type 1 cardiovascular endpoint trials published	Type 1 CVD risk differs from type 2; extrapolation not recommended

Biomarker Predispositions and Individual Response Readiness

Individual genetic variants in GLP-1 receptor and metabolic pathways may influence treatment response likelihood, though genetic predisposition does not determine exact medication efficacy. Understanding these predispositions can support more informed discussions about whether GLP-1 therapy aligns with a patient's metabolic profile.

Biomarkers like insulin autoantibodies (IAAs), glutamic acid decarboxylase antibodies (GADAs), and zinc transporter 8 antibodies (ZnT8As) define type 1 autoimmunity severity and may correlate with residual beta-cell function. Preserved C-peptide levels, for instance, suggest retained insulin secretion capacity, which could theoretically influence GLP-1 response; however, this relationship remains under investigation and should not guide therapy without provider counsel.

Safety, Eligibility, and Provider-Guided Personalization

Type 1 diabetes patients considering semaglutide must undergo thorough baseline assessment including insulin requirement history, A1C control, hypoglycemia frequency, kidney function, thyroid status, and personal/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Off-label GLP-1 use in type 1 carries risks not fully characterized in regulatory trials.

Initiation and titration require close provider supervision with frequent glucose monitoring, insulin adjustment protocols, and clear communication about red flags. Type 1 patients should expect ongoing assessment rather than passive use; those with unstable insulin requirements, recurrent severe hypoglycemia, or advanced kidney disease may not be appropriate candidates without specialized endocrinology input.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in key peptide receptor pathways—including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609—that may help provide context for how an individual's metabolic system responds to GLP-1 signaling. In type 1 diabetes, these predispositions should be interpreted with a qualified healthcare provider as part of a comprehensive personalization assessment.

The genetic test reveals inherited predispositions in peptide pathways, not exact medication response or type 1 diabetes disease severity. For type 1 patients, this information may highlight which individuals have genetic markers associated with stronger GLP-1 receptor sensitivity or metabolic plasticity, supporting more nuanced provider conversations about whether GLP-1 therapy warrants trial in their specific clinical context.

When combined with clinical biomarkers (C-peptide levels, autoantibody profiles, kidney function) and metabolic history, PlexusDx genetic insights can support a more informed conversation between patient and provider about treatment readiness, monitoring intensity, and personalized approach to glycemic and weight management in type 1 diabetes.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.